Organization (Industry)
Abbott Rapid Dx
ClinicalTrials.gov lists Abbott Rapid Dx as lead sponsor of 12 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Abbott Rapid Dx: 12 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (17)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| COVID-19 | 7 |
| Myocardial Infarction | 3 |
| Acute Coronary Syndrome | 2 |
| Brain Injuries | 2 |
| Brain Injuries, Traumatic | 2 |
Showing 5 of 17 disease areas.
Trials by start year as sponsor or collaborator (12)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 6 |
| 2024 | 6 |
| 2023 | 4 |
| 2022 | 4 |
| 2021 | 2 |
| 2020 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 2 |
| 2014 | 1 |
Showing 10 of 12 years.
Recruitment duration, a model prediction: none of the 22 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 58% hit target (n=12) | 75% on time (n=12) |
Journals published in (18)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Annals of emergency medicine | 2 |
| Journal of the American College of Cardiology | 2 |
| Academic emergency medicine : official journal of the Society for Academic Emergency Medicine | 1 |
| American journal of clinical pathology | 1 |
| BMJ (Clinical research ed.) | 1 |
Showing 5 of 18 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 237 | 17 | 2025-10-21 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 2 |
FDA recalls (31)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| i-STAT EG7+ cartridge; List Number: 03P76-25; | Class II | 2026-04-01 |
| i-STAT EG6+ cartridge; List Number: 03P77-25; | Class II | 2026-04-01 |
| i-STAT G3+ cartridge; List Number: 03P78-26; | Class II | 2026-04-01 |
| i-STAT CG4+ cartridge (white). List Number: 03P85-25. | Class II | 2025-08-21 |
| i-STAT CG8+ cartridge. List Number: 03P88-25. 510(k) numbers: K894914, K940918, K223710, K230275, K230285, K230300 | Class II | 2025-08-21 |
Showing 5 of 31 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 4 | 2022-02-01 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| ABBOTT POINT OF CARE INC. | Princeton, US | FDA |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| National University of Medical Sciences, Pakistan | Co sponsors trial with | 1 |
Latest dated events (304)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-04-01 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-04-01 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-04-01 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2025-10-21 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-10-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 304 events.
CLIA clinical laboratory certificates (1)
| Lab | Certificate | Status |
|---|---|---|
| ABBOTT POINT OF CARE | Certificate of waiver | Terminated |
Biomarker capability evidence (6)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ZDHHC2 | Trial sponsor | Named in trial exclusion criteria |
| ZDHHC2 | Trial sponsor | Named in trial exclusion criteria |
| ZDHHC2 | Trial sponsor | Named in trial exclusion criteria |
| ZDHHC2 | Trial sponsor | Mentioned in trial text |
| ZDHHC2 | Trial sponsor | Mentioned in trial text |
Showing 5 of 6 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, climate targets, as filed, workforce and board diversity, as filed, and biomarkers this organization publishes on.